Tax Insight

Trump proposes tariffs on generic pharmaceuticals -- what companies should know

Insight
5 minute read
September 08, 2026

What happened?

President Trump on July 21 announced via social media a proposed tariff framework for imported generic pharmaceuticals to encourage domestic manufacturing. Under the announced framework, imported generic drugs would remain subject to no additional tariffs for a two-year transition period starting August 1, 2026. The tariff rate would then increase to 100% beginning August 1, 2028, and increase again to 200% beginning August 1, 2029. The announcement states that the existing policy applicable to patented, branded, and innovative pharmaceuticals would remain unchanged. Additional guidance or formal implementing actions have not yet been issued.

Why is it relevant?

This proposal could have significant implications for pharmaceutical manufacturers, importers, distributors, and healthcare stakeholders by substantially increasing the cost of importing generic pharmaceuticals into the United States while further incentivizing domestic manufacturing. Based on an estimated $27 billion in annual US customs import value for generic pharmaceutical products, the proposed tariffs could generate approximately $27 billion in additional annual duties beginning in August 2028 and increase to $54 billion annually beginning in August 2029 if import volumes and sourcing patterns remain unchanged.

Actions to consider

Companies that import generic pharmaceuticals into the United States should monitor developments relating to implementation of the proposed tariffs and evaluate their potential exposure. Businesses may wish to assess affected products, sourcing alternatives, contractual pricing arrangements, customs and transfer pricing implications, and potential opportunities to expand or relocate manufacturing operations in anticipation of the proposed tariff increases.

For more details, please read the full Tax Insight linked below.